The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)
Abstract
A randomized, controlled trial has begun to compare neoadjuvant chemotherapy using gemcitabine and S-1 with upfront surgery for patients planned resection of pancreatic cancer. Patients were enrolled after the diagnosis of resectable or borderline resectable by portal vein involvement pancreatic cancer with histological confirmation. They were randomly assigned to either neoadjuvant chemotherapy or upfront surgery. Adjuvant chemotherapy using S-1 was administered for 6 months to patients with curative resection who fully recovered within 10 weeks after surgery in both arms. The primary endpoint is overall survival; secondary endpoints include adverse events, resection rate, recurrence-free survival, residual tumor status, nodal metastases and tumor marker kinetics. The target sample size was required to be at least 163 (alpha-error 0.05; power 0.8) in both arms. A total of 360 patients were required after considering ineligible cases. This trial began in January 2013 and was registered with the UMIN Clinical Trials Registry (UMIN000009634).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Oettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
Klinkenbijl, J. H., Jeekel, J., Sahmoud, T., van Pel, R., Couvreur, M. L., Veenhof, C. H., Arnaud, J. P., Gonzalez, D. G., de Wit, L. T., Hennipman, A., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199912000-00006 · Cited by 1,286
Uesaka, K., Boku, N., Fukutomi, A., Okamura, Y., Konishi, M., Matsumoto, I., Kaneoka, Y., Shimizu, Y., Nakamori, S., Sakamoto, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30583-9 · Cited by 1,115
Self-citationUeno, H., Ioka, T., Ikeda, M., Ohkawa, S., Yanagimoto, H., Boku, N., Fukutomi, A., Sugimori, K., Baba, H., Yamao, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3680 · Cited by 628
Self-citationVersteijne, E., Vogel, J. A., Besselink, M. G., Busch, O. R. C., Wilmink, J. W., Daams, J. G., van Eijck, C. H. J., Groot Koerkamp, B., Rasch, C. R. N., & van Tienhoven, G. (2018) · British Journal of Surgery · doi:10.1002/bjs.10870 · Cited by 519
Ueno, H., Kosuge, T., Matsuyama, Y., Yamamoto, J., Nakao, A., Egawa, S., Doi, R., Monden, M., Hatori, T., Tanaka, M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605256 · Cited by 439
Self-citationAndriulli, A., Festa, V., Botteri, E., Valvano, M. R., Koch, M., Bassi, C., Maisonneuve, P., & Sebastiano, P. D. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2110-8 · Cited by 187
Motoi, F., Ishida, K., Fujishima, F., Ottomo, S., Oikawa, M., Okada, T., Shimamura, H., Takemura, S., Ono, F., Akada, M., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3129-9 · Cited by 145
Self-citationEuropean cancer mortality predictions for the year 2011
Malvezzi, M., Arfè, A., Bertuccio, P., Levi, F., Vecchia, C. L., & Negri, E. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq774 · Cited by 136
Cited by
Versteijne, E., Suker, M., Groothuis, K., Akkermans-Vogelaar, J. M., Besselink, M. G., Bonsing, B. A., Buijsen, J., Busch, O. R., Creemers, G.-J. M., van Dam, R. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02274 · Cited by 1,082
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Nevala-Plagemann, C., Hidalgo, M., & Garrido-Laguna, I. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0281-6 · Cited by 393
Neoadjuvant therapy for pancreatic cancer
Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00746-1 · Cited by 377
Lee, W., Park, H. J., Lee, H.-J., Jun, E., Song, K. B., Hwang, D. W., Lee, J. H., Lim, K., Kim, N., Lee, S. S., et al. (2022) · International Journal of Surgery · doi:10.1016/j.ijsu.2022.106851 · Cited by 35
de Scordilli, M., Michelotti, A., Zara, D., Palmero, L., Alberti, M., Noto, C., Totaro, F., Foltran, L., Guardascione, M., Iacono, D., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104013 · Cited by 7
Metadata
- Authors
- Motoi, F., Kosuge, T., Ueno, H., Yamaue, H., Satoi, S., Sho, M., Honda, G., Matsumoto, I., Wada, K., Furuse, J., Matsuyama, Y., Unno, M., & Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP)
- Venue
- Japanese Journal of Clinical Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-01-04
- Volume
- 49
- Issue
- 2
- Pages
- 190-194
- ISSN
- 0368-2811 (ISSN-L)
- 1465-3621
- OpenAlex
- W2908229190
- Cited by
- 530
- References
- 11
- FWCI
- 17.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). https://app.cochat.ai/papers/10.1093/jjco/hyy190
- The paper
- Motoi, F., Kosuge, T., Ueno, H., Yamaue, H., Satoi, S., Sho, M., Honda, G., Matsumoto, I., Wada, K., Furuse, J., Matsuyama, Y., Unno, M., & Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP). (2019). Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyy190
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.